Delcath Systems, Inc. (DCTH) - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Delcath Systems, Inc. is an interventional oncology company focused on treating primary and metastatic cancers to the liver. Its lead product, HEPZATO KIT, is FDA-approved for uveal melanoma with hepatic metastases. The company also markets CHEMOSAT in Europe. As of October 27, 2025, 35,313,718 shares of common stock were outstanding.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $20,563 | $11,200 | $64,503 | $22,105 |
| Gross Profit | $17,939 | $9,560 | $55,716 | $18,043 |
| Gross Margin | 87.2% | 85.4% | 86.4% | 81.6% |
| Operating Income (Loss) | $(388) | $(1,259) | $2,844 | $(15,449) |
| Net Income (Loss) | $830 | $1,864 | $4,596 | $(22,988) |
| Diluted EPS | $0.02 | $0.06 | $0.12 | $(0.84) |
| Cash & Equivalents | $41,813 | $8,315 | $41,813 | $8,315 |
| Short-term Investments | $47,099 | $5,700 | $47,099 | $5,700 |
| Total Debt | $0 | $0 | $0 | $0 |
Note: All debt was paid off in 2024. The company reported positive operating income for the first time in the nine-month period ended September 30, 2025.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 83.6% year-over-year for the nine months ended September 30, 2025, driven by commercial expansion of HEPZATO in the U.S. (22 facilities treated patients in 9M 2025 vs. 11 in 9M 2024) and CHEMOSAT in Europe.
- Profitability: The company transitioned from a net loss of $22.99 million in 9M 2024 to a net income of $4.60 million in 9M 2025. Operating loss narrowed significantly to a profit of $2.84 million.
- Expense Increases: R&D expenses rose 81% (9M 2025 vs. 2024) due to the initiation of Phase 2 clinical trials for metastatic colorectal cancer (mCRC) and metastatic breast cancer (mBC). SG&A expenses increased 46% due to commercial expansion and higher stock-based compensation.
- Liquidity: Cash and short-term investments grew from approximately $14 million at the end of 2024 to $88.9 million at September 30, 2025, bolstered by warrant exercises and operating cash flow.
Guidance, Outlook, and Risks
- Clinical Pipeline:
- CHOPIN Trial: Announced October 18, 2025. Combination of CHEMOSAT with immune checkpoint inhibitors showed superior 1-year progression-free survival (54.7% vs. 15.8%) and overall survival compared to monotherapy.
- mCRC Trial: Enrollment began in Q3 2025. Primary endpoint (hepatic PFS) expected end of 2027.
- mBC Trial: FDA IND cleared April 2025. Enrollment expected to begin Q1 2026.
- Regulatory & Pricing: The company entered into a National Drug Rebate Agreement (NDRA) and Pharmaceutical Pricing Agreement (PPA) with CMS, requiring 340B pricing starting July 1, 2025. Compliance with these programs is critical to avoid penalties.
- Tax Legislation: The "One Big Beautiful Bill" (OBBB) signed July 4, 2025, restored immediate expensing of R&D costs, reducing the current tax provision for the period.
- Liquidity Outlook: Management believes current cash and investments are sufficient to fund operations for at least 12 months.
- Risks: Key risks include failure to comply with government pricing programs (Medicaid/340B), supply chain disruptions, and the uncertainty of clinical trial outcomes for new indications.
Investor Verification Checklist
- Revenue Sustainability: Verify the rate of new facility adoption for HEPZATO and the impact of the new 340B pricing agreements on gross margins.
- Cash Burn vs. Generation: Confirm the sustainability of positive operating cash flow ($14.3M in 9M 2025) as R&D spending increases for new Phase 2 trials.
- Clinical Trial Progress: Monitor enrollment rates for the mCRC and mBC trials and the timeline for primary endpoint readouts (2027-2028).
- Regulatory Compliance: Assess the company's internal controls for calculating and reporting Medicaid rebates and 340B ceiling prices to avoid civil penalties.
- Contingent Liabilities: Review the status of the medac settlement liability ($0.8M recorded) and potential future royalty obligations.